证券代码：688136 证券简称：科兴制药 公告编号：2025-033 科兴生物制药股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/11 | 2025/6/12 | 2025/6/12 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经科兴生物制药股份有限公司（以下简称"公司"）2025 年 5 月 8 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所 上市公司自律监管指引第 7 号——回购股份》等相关法律、行政法规、部门规章 及其他规范性文件以及《公司章程》的有关规定，公司回 ...

Market Overview - A-shares experienced a rally in the afternoon, with the ChiNext Index and the STAR Market Index both rising over 1% [1] - The Shanghai Composite Index closed up 0.23% at 3384.1 points, while the Shenzhen Component Index rose 0.58% to 10203.5 points [1] - The total trading volume in the Shanghai and Shenzhen markets reached 13.172 billion yuan, an increase of nearly 1.4 billion yuan compared to the previous day [1] Sector Performance - The food and beverage sector saw a pullback, with Yanjinpuzi dropping over 8% [1] - Pharmaceutical stocks also weakened, with Jinkai Biotechnology down nearly 10% and Sinovac Biotech falling over 8% [1] - The CPO concept stocks surged, with Shengyi Electronics and Haide Control hitting the daily limit [3][4] - The computing power concept stocks were strong, with Huijin Co. and Qingyun Technology also reaching the daily limit [1][3] - The virtual power plant concept gained traction, with Hengshi Technology and Ankao Zhidian both hitting the daily limit [7][8] - The sports concept remained active, with Jinling Sports achieving a three-day limit increase and Gongchuang Lawn hitting the limit for four consecutive days [9][10] CPO Concept - The CPO concept saw significant gains, with Shengyi Electronics closing at a 20% limit increase [3][4] - Other notable performers included Shijia Photon and Haide Control, both reaching their daily limits [3][4] Virtual Power Plant Concept - The virtual power plant concept also experienced a strong performance, with Hengshi Technology closing at a 20% limit increase [7][8] - Other companies in this sector, such as Ankao Zhidian and Jinzhi Technology, also saw substantial gains [7][8] Sports Sector - The sports sector showed continued strength, with Jinling Sports achieving a 20% limit increase and a cumulative increase of approximately 94% over four days [9][10] - The Jiangsu Province City Football League attracted significant attendance, boosting local tourism and consumption [11] Policy Developments - The National Energy Administration has initiated pilot projects focusing on new power system construction, including virtual power plants and intelligent microgrids [8][9] - The National Development and Reform Commission and the Energy Administration have introduced policies to promote green electricity connections, enhancing the traceability of renewable energy consumption [9]

Group 1: New Consumption Stocks - The new consumption stocks, including Pop Mart, Lao Pu Gold, and Mixue Group, experienced significant declines, with Lao Pu Gold down 9%, Mixue Group down 7%, and Pop Mart down 1% [3][6] - These stocks had previously seen massive gains, with Lao Pu Gold increasing by 23 times and Pop Mart rising from 8.6 HKD to 256 HKD over two and a half years, leading to high market expectations [6] - Current valuations are concerning, with Pop Mart's P/E ratio at 96, Lao Pu Gold at 99, and Mixue Group at 46, indicating potential overvaluation [6][9] Group 2: Pharmaceutical Sector - The pharmaceutical sector has seen a notable pullback, with various segments such as CRO, medical aesthetics, generic drugs, and innovative drugs experiencing significant declines [10] - Individual stocks like Jinkai Biotechnology fell by 9.79%, and other popular stocks like Qianhong Pharmaceutical and Kexing Pharmaceutical also showed marked declines [11][13] Group 3: Sports Industry - The "Su Super League" has gained immense popularity, driving related sports stocks in the A-share market to surge, with Jinling Sports hitting a 20% limit up for three consecutive days, totaling a 104% increase over five trading days [19] - The league's matches have seen high attendance, with some matches exceeding attendance levels of the Chinese Super League, indicating strong market interest [19][20] Group 4: Military Equipment Sector - The military equipment sector is leading the market, with several companies disclosing restructuring progress related to the China Ordnance Equipment Group, resulting in stock price increases for companies like Dong'an Power and Huasheng Technology [22][23] - The restructuring is part of a broader initiative approved by the State Council, which is expected to enhance operational efficiency and market positioning for the involved companies [22]

中国经济网北京6月5日讯科兴制药(688136.SH)昨晚发布股东减持股份计划公告。截至公告披露日，深 圳科益医药控股有限公司(以下简称"科益医药")直接持有科兴制药131,778,347股，占公司总股本的比例 为66.01%。科益医药直接持有的股份为其在公司首次公开发行前取得的股份，上述股份均已上市流 通。 科兴制药2020年以来3次分红合计派发现金红利5158.71万元。 科益医药本次拟通过集中竞价或大宗交易方式减持所持有的公司股份为不超过5,989,200股，即不超过公 司目前股份总数的3.00%。本次减持计划自公告披露之日起15个交易日后的3个月内(根据中国证券监督 管理委员会及上海证券交易所规定禁止减持的期间除外)进行。若减持计划实施期间公司发生送股、资 本公积金转增股本、配股等股份变动事项，将对拟减持股份数量和比例进行相应调整。 科兴制药2024年年度报告显示，深圳科益医药控股有限公司为公司控股股东，邓学勤为公司实际控制 人。 公司第二届董事会第二十二次会议审议通过《关于公司2024年度利润分配方案的议案》，公司2024年度 利润分配预案为：拟以实施权益分派股权登记日的总股本为基数，向全体股东按每 ...

Core Viewpoint - The collaboration between Kexing Pharmaceutical and Dongyao Pharmaceutical has led to the approval of a biosimilar product, Bevacizumab injection, by the Nigerian Food and Drug Administration, marking a significant advancement in the company's strategy in the African pharmaceutical market [1] Group 1 - The approved Bevacizumab injection is indicated for the treatment of metastatic colorectal cancer, advanced or metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and cervical cancer [1] - The approval signifies an important step for the company in establishing its presence in the core pharmaceutical market of Africa [1]

Group 1 - Weijie Chuangxin plans to reduce its shareholding by up to 3%, amounting to no more than 12.91 million shares, due to personal funding needs [1] - Lier Chemical's major shareholder intends to reduce its stake by up to 3%, equivalent to no more than 24.01 million shares, for investment returns [1] - Helin Micro-Nano's controlling shareholder plans to reduce its shareholding by up to 1.5%, which is no more than 1.75 million shares, due to personal funding needs [2] Group 2 - Yifan Pharmaceutical received drug registration certificates for two products, indicating a focus on oncology and leukemia treatments [3] - *ST Jinbi is planning a change in control, leading to a temporary suspension of its stock trading [4] - Kexing Pharmaceutical's shareholder plans to reduce its stake by up to 3%, amounting to no more than 5.90 million shares, to optimize the equity structure [7] Group 3 - Li New Energy plans to invest approximately 1.25 billion yuan in three independent energy storage projects [7] - Kingsoft Office intends to acquire the remaining 31.98% stake in its subsidiary for 254 million yuan, aiming for full ownership [8] - Northeast Pharmaceutical received a CEP certificate from the European Medicines Agency for an antibiotic raw material, enhancing its product credibility [9] Group 4 - Tai'er Co. announced the lifting of a detention order on its controlling shareholder, changing it to a notice of supervision [10] - Runjian Co. won a bid for a solar power project worth approximately 83.92 million yuan, highlighting its role in the energy sector [11] - Jiuan Medical plans to register and issue medium-term notes and short-term financing bonds, with a total scale of up to 35 billion yuan and 5 billion yuan respectively [12] Group 5 - Wanma Co.'s chairman resigned due to work adjustments, but will remain as a board member [13] - Changhua Chemical plans to transfer 1% of its shares through an inquiry transfer method due to personal funding needs [14] - Jinkai Biotechnology's two shareholders plan to reduce their combined stake by up to 4%, totaling 481.6 thousand shares [15] Group 6 - Aeston plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [16] - Maiwei Biotechnology's chairman proposed a share buyback plan with a total amount between 25 million and 50 million yuan [17] - Montai High-tech's specific shareholders and executives plan to reduce their stake by up to 3.03%, citing personal funding needs [18] Group 7 - *ST Dongjing's stock will resume trading after a change in control, with a new actual controller [20] - Tongdahai's major shareholders plan to reduce their combined stake by up to 3.57%, totaling 345.24 thousand shares [23]

Group 1 - The Ministry of Industry and Information Technology emphasizes the need for a systematic approach to promote the development of the artificial intelligence industry and empower new industrialization [2] - The National Energy Administration is coordinating the planning of computing power and electricity projects to enhance the green electricity ratio for data centers [1] - The State-owned Assets Supervision and Administration Commission has approved the separation of the automotive business from the China Weaponry Equipment Group, creating an independent central enterprise [4][10] Group 2 - In May 2025, A-share new account openings reached 1.56 million, a year-on-year increase of 22.86% [3] - Wantai Biological's nine-valent HPV vaccine has been approved for market release, targeting women aged 9-45 [4][5] - Hainan Huatie is planning to issue shares overseas and list on the Singapore Exchange [5] Group 3 - Yuxin Technology is providing stablecoin-related services to overseas financial institutions, integrating into its international business expansion [5] - Kexing Pharmaceutical's controlling shareholder plans to reduce its stake by up to 3% [5] - Estun plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [6] Group 4 - Dongfeng Motor Company has notified that it will not be involved in asset and business restructuring at this time [7] - ST Dongjing is undergoing a change in control, with shares resuming trading on June 5, 2025 [8] - Huamao Technology plans to acquire the remaining 57.84% stake in Fuchuang Youyue, which will become a wholly-owned subsidiary [9] Group 5 - Honghe Technology is planning a change in control, with shares suspended from trading [12] - Zhongke Electric is investing up to 8 billion yuan to establish a lithium-ion battery anode material integrated base project in Oman [13] - Hexing Co., Ltd. has reported that some executives have reduced their holdings during a period of stock price volatility [15]

Group 1 - The Ministry of Industry and Information Technology emphasizes the deployment of large models in key manufacturing sectors and the cultivation of AI application service providers [1] - The Ministry of Finance and the Ministry of Housing and Urban-Rural Development plan to support urban renewal actions in 20 cities, including Beijing and Tianjin [2] - The National Energy Administration is conducting pilot projects for new power systems, focusing on the coordination of data center green electricity demand and renewable energy resources [3] Group 2 - In May, the wholesale sales of new energy passenger vehicles in China reached 1.24 million units, a year-on-year increase of 38% [7] - Guangzhou Port's Nansha Port Authority completed the first "sea transfer for certificate" business in the province, streamlining the process for enterprises [8] - Sichuan Province proposes extending marriage leave from 5 days to 20 days and increasing maternity leave based on the number of children [9] Group 3 - Wantai Biological Pharmacy announced that its subsidiary has received approval for the nine-valent human papillomavirus vaccine [10] - Kweichow Moutai reported a total expenditure of 5.1 billion yuan for repurchasing 3.31 million shares by the end of May [11] Group 4 - Companies such as Shangluo Electronics and Huamao Technology are planning acquisitions to enhance their market positions [12] - Several companies are preparing for H-share listings on the Hong Kong Stock Exchange, indicating a trend of international expansion [14] - *ST Dongjing and *ST Jinbi are undergoing control changes, with stock trading resuming on June 5 [16] Group 5 - The U.S. stock market showed mixed results, with the Dow Jones down 0.22% and the Nasdaq up 0.32% [19] - The Federal Reserve's Beige Book indicates a slowdown in economic activity and a decrease in labor demand [20] - OpenAI reports over 3 million paid enterprise users, projecting revenue of $12.7 billion for the year [22]

Market News - The three major US stock indices closed mixed, with the Dow Jones down 0.22%, the Nasdaq up 0.32%, and the S&P 500 up 0.01% [1] - Popular tech stocks showed varied performance, with Meta rising over 3%, Broadcom and AMD up over 1%, while Tesla fell over 3% [1] - The Nasdaq Golden Dragon China Index rose by 2.04%, with most popular Chinese concept stocks increasing, including NIO up over 6% and Alibaba, Xpeng, and Kingsoft up over 3% [1] - COMEX gold futures rose by 0.6% to $3397.4 per ounce, while WTI crude oil futures fell by 0.88% to $62.85 per barrel [1] - Major European stock indices closed higher, with Germany's DAX up 0.7%, France's CAC40 up 0.58%, and the UK's FTSE 100 up 0.16% [1] Industry Insights - The Hong Kong Securities and Futures Commission is considering introducing virtual asset derivatives trading for professional investors, aiming to enhance risk management and optimize tax incentives for virtual assets [2] - This initiative may lead to more virtual asset ETFs and structured products, promoting the integration of traditional finance with virtual asset technology [2] - The National Energy Administration has announced pilot projects for new power systems, focusing on virtual power plants to enhance flexibility and renewable energy consumption [3] - By 2027 and 2030, the goal is to achieve 20 million kW and 50 million kW of regulation capacity for virtual power plants, respectively [3] - The development of exoskeleton robots is advancing towards consumer markets, with applications expanding from medical rehabilitation to home care and outdoor activities, indicating a market potential exceeding hundreds of billions [5]

Group 1: Domestic Vaccine Developments - Wantai Biologics has received approval for its nine-valent HPV vaccine, making it the first domestic nine-valent HPV vaccine in China and the second globally [1] - The approval is significant as it fills a gap in the domestic market, potentially impacting the pricing and competitive landscape of HPV vaccines [1] Group 2: Oncology Drug Approvals - AstraZeneca's drug, Imfinzi (durvalumab), has been approved for use in adult patients with limited-stage small cell lung cancer (LS-SCLC) who have not shown disease progression after platinum-based chemotherapy [2] - The drug is expected to improve survival rates significantly, with over half of the patients achieving a three-year survival milestone [2] Group 3: Compliance Issues in Pharmaceutical Sales - Kangfang Biologics is facing scrutiny after a sales representative allegedly forged documents to obtain anti-cancer drugs intended for clinical research, raising concerns about compliance in sales management [3] - The incident highlights potential vulnerabilities in the company's sales practices and may negatively impact its brand image and market trust [3] Group 4: Clinical Trials for New Vaccines - Baike Biologics has received approval for clinical trials of its recombinant shingles vaccine, aimed at adults aged 40 and above, which could enhance the company's product portfolio and long-term profitability [4] Group 5: Shareholder Actions - Sinovac Biotech's controlling shareholder plans to reduce its stake by up to 3%, which may be interpreted as a signal for profit-taking after a significant stock price increase of over 150% this year [5] - The reduction aims to optimize the company's equity structure and improve liquidity in the secondary market [5]